Enanta is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field.
Enanta Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ENTA) : November 24, 2017 Fri, 24 Nov 2017 16:18:52 +0000 Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Enanta Pharmaceuticals, Inc. a score of 75. Our analysis is based on comparing Enanta Pharmaceuticals, Inc. with the following peers – Achillion Pharmaceuticals, Inc., Enzon Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, Johnson & Johnson, AbbVie, Inc., Novartis AG Sponsored ADR, Merck & Co., Inc. and Bristol-Myers Squibb Company ... Read more
(Read more...)
Enanta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ENTA-US : November 22, 2017 Wed, 22 Nov 2017 12:53:39 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Enanta Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
ETFs with exposure to Enanta Pharmaceuticals, Inc. : November 21, 2017 Tue, 21 Nov 2017 16:41:11 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Enanta Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ENTA-US. Comparing the performance and risk of Enanta Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
Enanta Pharmaceuticals posts 4Q profit Mon, 20 Nov 2017 21:25:55 +0000 The Watertown, Massachusetts-based company said it had profit of $1.86 per share. The biotechnology company posted revenue of $75.9 million in the period. For the year, the company reported profit of $17.7 ...
Enanta Pharmaceuticals, Inc. to Host Earnings Call Mon, 20 Nov 2017 17:00:00 +0000 NEW YORK, NY / ACCESSWIRE / November 20, 2017 / Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) will be discussing their earnings results in their Q4 Earnings Call to be held on November 20, 2017 at 4:30 ...
Enanta Pharmaceuticals Ranked as One of North America’s Fastest Growing Companies on Deloitte’s 2017 Technology Fast 500™ Fri, 10 Nov 2017 12:30:00 +0000 Enanta Pharmaceuticals, Inc. , a chemistry-driven biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced its inclusion on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America.
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.